Iovance Biotherapeutics, Inc. (IOVA) stock
Close on Nov 13, 2026Market cap $3.52BP/E –Yield –
Iovance Biotherapeutics, Inc. grew revenue 51.3% to $378.98M over the twelve months to Sep 30, 2026. Free cash flow was -$216.06M. At the latest close the market valued the company at $3.52B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $3.52B
- P/E ratio
- –
- Price to sales
- 9.27
- Price to book
- 4.33
- Dividend yield
- –
- Free cash flow yield
- -6.15%
Fundamentals
- Revenue
- $378.98M
- Net income
- -$220.54M
- EPS, diluted
- -$1.09
- Free cash flow
- -$216.06M
- Book value per share
- $1.78
- Diluted shares
- 456M
Trading
- Next earnings
- Feb 23, 2027 (estimated, before the open)
- Previous close
- $7.63
- Open
- $7.80
- Day's range
- $7.46 – $7.83
- Volume
- 11,675,180
- Average volume (20 days)
- 15,398,407
- Index membership
- Russell 2000 (since Jun 2022), Russell 3000
- Beta (5 years)
- 1.28
- 52-week range
- $2.08 – $15.37
- RSI (14 days)
- 32.8
- Volatility (1 year)
- 108.4%
- Relative volume
- 0.69×
- WACC
- 11.5%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | IOVA | S&P 500 | Difference | IOVA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -46.5% | -3.0% | −43.4 pts | ||
| 3 months | +19.0% | -2.8% | +21.8 pts | ||
| Year to date | +184.2% | +11.5% | +172.8 pts | ||
| 1 year | +222.0% | +13.5% | +208.5 pts | ||
| 3 years | +92.6% | +77.7% | +14.9 pts | +24.4% | +21.1% |
| 5 years | -63.2% | +72.6% | −135.8 pts | -18.1% | +11.5% |
| 10 years | +2.1% | +308.2% | −306.1 pts | +0.2% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Iovance Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- News
- News
- News
- News
About Iovance Biotherapeutics
Biological Products, (No Diagnostic Substances)
Iovance Biotherapeutics is a commercial-stage biotechnology company that develops and delivers individualized tumor-infiltrating lymphocyte cell therapies for patients with solid tumor cancers. Its primary commercial offerings are Amtagvi, a one-time T-cell therapy for adults with advanced melanoma who have undergone prior treatments, and Proleukin, an injectable interleukin-2 medication utilized in cancer treatment regimens and cellular manufacturing. The company distributes its therapies and pharmaceutical products to specialized authorized treatment centers, healthcare professionals, commercial medicine distributors, and biomedical research institutions treating adult oncology patients.
Company profile, executives and historyIovance Biotherapeutics stock: common questions
What is Iovance Biotherapeutics's stock price?
IOVA closed at $7.76 on Nov 13, 2026, up 1.70% on the day. Over the past 52 weeks it traded between $2.08 and $15.37.
What is Iovance Biotherapeutics's market cap?
Iovance Biotherapeutics was worth $3.52B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is IOVA's P/E ratio?
Iovance Biotherapeutics lost money over fiscal 2025 (diluted EPS -$1.09), so it has no meaningful P/E ratio.
How much revenue does Iovance Biotherapeutics make?
Iovance Biotherapeutics reported revenue of $378.98M for the twelve months to Sep 30, 2026, up 51.3% from a year earlier.
Does Iovance Biotherapeutics pay a dividend?
No. Iovance Biotherapeutics has not paid a cash dividend over the last twelve months.
When does Iovance Biotherapeutics report earnings next?
Iovance Biotherapeutics is expected to report Q4 FY2026 results on Feb 23, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IOVA stock performed over the past year?
Including dividends, IOVA returned +222.0% over the past year, against +13.5% for the S&P 500.
How many IOVA shares are sold short?
65M shares were sold short at the latest FINRA report, 14.45% of the float, or 4.2 days of average trading volume.
Who are Iovance Biotherapeutics's competitors?
Companies most similar to Iovance Biotherapeutics by business, industry and size include IMCR, IBRX, ADAPY, AUTL, ALVO.
See a number that looks wrong?